Interleukin 17E (IL-17E)

Interleukin 17E (IL-17E), also widely known as Interleukin 25 (IL-25), is a distinct member of the IL-17 cytokine family that plays a pivotal role in orchestrating Type 2 (Th2) immune responses [2, 7]. Unlike the founding member IL-17A, which primarily drives neutrophilic inflammation, IL-17E promotes the recruitment and activation of eosinophils and the production of Th2-associated cytokines such as IL-4, IL-5, and IL-13 [6, 11]. It signals through a heterodimeric receptor complex consisting of IL-17RA and IL-17RB, which is expressed on various immune cells including Th2 cells, mast cells, and group 2 innate lymphoid cells (ILC2s) [13, 19]. In disease states, IL-17E is heavily implicated in the pathogenesis of allergic conditions such as asthma, atopic dermatitis, and chronic rhinosinusitis, where its overexpression drives chronic airway and skin inflammation [4, 13, 24]. Conversely, some studies suggest IL-17E may possess antitumor properties in specific cancers, such as melanoma and pancreatic cancer, by activating B cells and eosinophils [5, 32]. Therapeutic strategies targeting IL-17E involve monoclonal antibodies designed to neutralize the cytokine or block its receptor complex, with several candidates having entered clinical trials for respiratory and inflammatory disorders [24, 37].

Other names

Interleukin 25IL-25IL17EInterleukin-25

Neutralization of the IL-17E cytokine or blockade of its receptor complex (IL-17RA/IL-17RB) to inhibit the induction of Type 2 (Th2) immune responses and eosinophilic inflammation [6, 19, 24].